Feedback PLC Letter of Intent signed and trading update (9462A)
30 März 2017 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 9462A
Feedback PLC
30 March 2017
30 March 2017
Feedback plc
("Feedback", the "Group" or the "Company")
Letter of Intent signed with leading global medical imaging
company and trading update
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to update shareholders on current developments. The
Group's efforts are being concentrated on obtaining the CE mark for
TexRAD Lung by the target date of May 2017. The CE mark will allow
the sale of TexRAD Lung in the EU and certain other markets as a
medical device which provides analysis of PET/CT images for
clinical use. As part of the intended distribution arrangements,
Feedback's subsidiary company, Cambridge Computed Imaging Ltd
("CCI"), has signed a Letter of Intent with a leading global
medical imaging company which would make TexRAD Lung available for
purchase on its diagnostic imaging solutions platform. This would,
in due course, enable easy access to TexRAD Lung for hundreds of
potential users around the world on a subscription basis.
CCI continues to pursue its ongoing discussions with other
leading imaging companies to broaden the range of potential routes
to market for clinical versions of TexRAD. CCI has also been very
active in finalising arrangements for the secure transfer of
patient data from Papworth Hospital NHS Foundation Trust to the new
Cambridge Biomedical Campus ahead of the move there in April 2018.
CCI has provided and maintained the software to store and display
medical images at Papworth Hospital since 2001 and is excited at
the challenge of transferring the extensive archive of medical
images.
New purchase orders for the well-established TexRAD research
version are continuing at a good rate ahead of the impending
release of the first clinical version with keen interest being
shown in India, the US and the UK. There remain significant
opportunities for TexRAD in China and South Korea and some
additional professional and legal costs have been incurred
regarding advice on new distribution and licensing agreements which
could substantially increase future revenues. As previously
indicated, TexRAD-related revenue in the second half of the
Company's financial year is expected to be substantially ahead of
that reported for the first half and the Company is on track to
report increased revenue for the financial year as a whole.
For further information contact:
Feedback plc Tel: 01954 718072
Alastair Riddell
Allenby Capital Limited (Nominated Tel: 020 3328
Adviser and Joint Broker) 5656
David Worlidge / Virginia Bull/
James Thomas
Northland Capital Partners Ltd (Joint Tel: 020 3861
Broker) 6625
Patrick Claridge / Margarita Mitropoulou
Peterhouse Corporate Finance Ltd Tel: 020 7469
(Joint Broker) 0936
Lucy Williams / Duncan Vasey
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFERVEIAFID
(END) Dow Jones Newswires
March 30, 2017 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024